Improving the lives of patients by
developing proprietary, innovative
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal
-
Public funding and Seal of Excellence already awardedSeal of excellence awarded by the European Innovation Council which enables the company to secure EUR 2.5M in non-dilutive, non-returnable funding (application submitted October 2023).
In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value -
Public funding and Seal of Excellence already awardedSeal of excellence awarded by the European Innovation Council which enables the company to secure EUR 2.5M in non-dilutive, non-returnable funding (application submitted October 2023). Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation Clinical trials completed and medical device certification obtained, enterprise value